Endo Fha Fertility Clomiphene Citrate Trial Estrogen

---
name: endo-fha-fertility-clomiphene-citrate-trial-estrogen
description: This skill suggests a trial of clomiphene citrate for ovulation induction in women with functional hypothalamic amenorrhea (FHA) who have an adequate endogenous estrogen level, as determined by baseline estradiol measurement. Use when a clinician asks, 'Her estrogen is measurable—should we try clomiphene?' Triggers include language like 'If E2 is sufficient, try clomiphene' or 'Consider clomiphene after confirming estrogen production'.
---

# Trial of clomiphene citrate for ovulation induction if sufficient endogenous estrogen level

## STEP 1 — Gather Information
Confirm FHA diagnosis by excluding pregnancy, anatomic/organic pathology, and other endocrine disorders; obtain baseline estradiol (E2) level, body mass index (BMI), and verify the patient desires conception after a complete fertility workup.

## STEP 2 — Rule In / Rule Out
If baseline estradiol is measurable and ≥20 pg/mL (indicating sufficient endogenous estrogen), proceed to evaluate for clomiphene trial; if E2 is <20 pg/mL or undetectable, rule out clomiphene and consider estrogen replacement or gonadotropin therapy instead.

## STEP 3 — Classify or Stratify
If E2 sufficient, further classify as candidate for clomiphene only when BMI ≥18.5 kg/m² and the patient has attempted to normalize energy balance (e.g., weight gain, nutritional rehabilitation); otherwise, prioritize energy balance correction before ovulation induction.

## STEP 4 — Decide
For candidates, initiate a trial of clomiphene citrate 50 mg daily for 5 days early in the menstrual cycle (or after a progestin‑induced bleed) with ovulation monitoring; for non‑candidates, address estrogen deficiency or weight normalization first and reconsider clomiphene after thresholds are met.

## Clinical Guardrails / Mimics / Pitfalls
Do not use clomiphene when E2ene if estradiol is persistently <20 pg/mL, as response is unlikely; avoid in BMI < 18.5 kg/m² without prior weight gain due to increased risk of fetal loss and preterm labor; do not exceed six cycles without reassessment; monitor for ovarian hyperstimulation syndrome (rare) and ensure no hepatic contraindication.

## Concrete Clinical Example
A 28‑year‑old woman with 6 months of amenorrhea, BMI 20.2 kg/m², baseline E2 35 pg/mL, FSH 6 IU/L, LH 5 IU/L, after exclusion of pregnancy, thyroid disease, prolactinoma, and uterine pathology, desires pregnancy. She completed 3 months of nutritional counseling with stable weight. Clomiphene citrate 50 mg daily for 5 days (cycle day 2‑5) was started; mid‑luteal progesterone confirmed ovulation in the second cycle, and she conceived.

**Source:** Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline, Gordon et al., 2017, https://doi.org/10.1210/jc.2017-00131